FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183455959> ?p ?o ?g. }

• W2183455959 endingPage "305" @default.
• W2183455959 startingPage "305" @default.
• W2183455959 abstract "A considerable proportion of non-small cell lung carcinoma (NSCLC) patients are ineligible for radical therapies. Many are frail not to tolerate intravenous palliative chemotherapy either. These patients often receive palliative radiotherapy (RT), or supportive care alone. We intend to compare outcomes with palliative RT alone, versus palliative RT plus oral low dose metronomic cyclophosphamide.Data was mined from 139 eligible NSCLC patient records. Comparisons were made between 65 patients treated from January 2011 to March 2013 with palliative RT (20-30 Gray in 5-10 fractions) alone, versus 74 patients treated from April 2013 to December 2014 with palliative RT plus oral metronomic cyclophosphamide (50 mg once daily from day of initiation of RT until at least the day of disease progression). Response was assessed after 1-month post-RT by computed tomography. Patients with complete or partial response were recorded as responders. For the determination of progression free survival (PFS), progression would be declared in case of increase in size of lesions, development of new lesions, or development of effusions. The proportions of responders were compared with the Fisher exact test, and the PFS curves were compared with the log-rank test.Differences in response rates were statistically insignificant. The PFS was significantly higher when metronomic chemotherapy was added to RT in comparison to treatment with RT alone (mean PFS 3.1 vs. 2.55 months; P=0.0501). Further histological sub-group analysis revealed that the enhanced outcomes with addition of metronomic cyclophosphamide to RT were limited to patients with adenocarcinoma histology (3.5 vs. 2.4 months; P=0.0053), while there was no benefit for those with squamous cell histology (2.6 vs. 2.6 months; P=1). At the dose of oral cyclophosphamide used, there was no recorded instance of any measurable hematological toxicity.For pulmonary adenocarcinoma patients, the treatment with palliative RT plus oral metronomic cyclophosphamide is better than that with palliative RT alone. However, for pulmonary squamous cell carcinoma the addition of oral metronomic cyclophosphamide to palliative RT offered no benefit. Further studies with similar and different metronomic chemotherapy agents are justifiable." @default.
• W2183455959 created "2016-06-24" @default.
• W2183455959 creator A5013417559 @default.
• W2183455959 creator A5030242013 @default.
• W2183455959 creator A5043309614 @default.
• W2183455959 creator A5055630282 @default.
• W2183455959 creator A5084335098 @default.
• W2183455959 creator A5084429374 @default.
• W2183455959 date "2015-11-01" @default.
• W2183455959 modified "2023-09-23" @default.
• W2183455959 title "The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma." @default.
• W2183455959 cites W1412922529 @default.
• W2183455959 cites W144604441 @default.
• W2183455959 cites W171704644 @default.
• W2183455959 cites W1964601122 @default.
• W2183455959 cites W2005244154 @default.
• W2183455959 cites W2016729118 @default.
• W2183455959 cites W2025127953 @default.
• W2183455959 cites W2061401090 @default.
• W2183455959 cites W2065436947 @default.
• W2183455959 cites W2075959323 @default.
• W2183455959 cites W2076686288 @default.
• W2183455959 cites W2098464561 @default.
• W2183455959 cites W2118841339 @default.
• W2183455959 cites W2135630936 @default.
• W2183455959 cites W2137813333 @default.
• W2183455959 cites W2139248078 @default.
• W2183455959 cites W2155263737 @default.
• W2183455959 cites W2161714684 @default.
• W2183455959 cites W2163659684 @default.
• W2183455959 cites W2286122960 @default.
• W2183455959 cites W2962783505 @default.
• W2183455959 doi "https://doi.org/10.3978/j.issn.2305-5839.2015.11.25" @default.
• W2183455959 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4669322" @default.
• W2183455959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26697465" @default.
• W2183455959 hasPublicationYear "2015" @default.
• W2183455959 type Work @default.
• W2183455959 sameAs 2183455959 @default.
• W2183455959 citedByCount "5" @default.
• W2183455959 countsByYear W21834559592016 @default.
• W2183455959 countsByYear W21834559592017 @default.
• W2183455959 countsByYear W21834559592019 @default.
• W2183455959 countsByYear W21834559592020 @default.
• W2183455959 crossrefType "journal-article" @default.
• W2183455959 hasAuthorship W2183455959A5013417559 @default.
• W2183455959 hasAuthorship W2183455959A5030242013 @default.
• W2183455959 hasAuthorship W2183455959A5043309614 @default.
• W2183455959 hasAuthorship W2183455959A5055630282 @default.
• W2183455959 hasAuthorship W2183455959A5084335098 @default.
• W2183455959 hasAuthorship W2183455959A5084429374 @default.
• W2183455959 hasConcept C121608353 @default.
• W2183455959 hasConcept C126322002 @default.
• W2183455959 hasConcept C143998085 @default.
• W2183455959 hasConcept C159110408 @default.
• W2183455959 hasConcept C2776256026 @default.
• W2183455959 hasConcept C2776694085 @default.
• W2183455959 hasConcept C2776755627 @default.
• W2183455959 hasConcept C2777546739 @default.
• W2183455959 hasConcept C2778822529 @default.
• W2183455959 hasConcept C2780739268 @default.
• W2183455959 hasConcept C2781182431 @default.
• W2183455959 hasConcept C2994186709 @default.
• W2183455959 hasConcept C509974204 @default.
• W2183455959 hasConcept C71924100 @default.
• W2183455959 hasConceptScore W2183455959C121608353 @default.
• W2183455959 hasConceptScore W2183455959C126322002 @default.
• W2183455959 hasConceptScore W2183455959C143998085 @default.
• W2183455959 hasConceptScore W2183455959C159110408 @default.
• W2183455959 hasConceptScore W2183455959C2776256026 @default.
• W2183455959 hasConceptScore W2183455959C2776694085 @default.
• W2183455959 hasConceptScore W2183455959C2776755627 @default.
• W2183455959 hasConceptScore W2183455959C2777546739 @default.
• W2183455959 hasConceptScore W2183455959C2778822529 @default.
• W2183455959 hasConceptScore W2183455959C2780739268 @default.
• W2183455959 hasConceptScore W2183455959C2781182431 @default.
• W2183455959 hasConceptScore W2183455959C2994186709 @default.
• W2183455959 hasConceptScore W2183455959C509974204 @default.
• W2183455959 hasConceptScore W2183455959C71924100 @default.
• W2183455959 hasIssue "20" @default.
• W2183455959 hasLocation W21834559591 @default.
• W2183455959 hasOpenAccess W2183455959 @default.
• W2183455959 hasPrimaryLocation W21834559591 @default.
• W2183455959 hasRelatedWork W2019694656 @default.
• W2183455959 hasRelatedWork W2357406576 @default.
• W2183455959 hasRelatedWork W2358156577 @default.
• W2183455959 hasRelatedWork W2364854402 @default.
• W2183455959 hasRelatedWork W2378830451 @default.
• W2183455959 hasRelatedWork W2389930763 @default.
• W2183455959 hasRelatedWork W2407189953 @default.
• W2183455959 hasRelatedWork W2425645265 @default.
• W2183455959 hasRelatedWork W2552718600 @default.
• W2183455959 hasRelatedWork W1899415052 @default.
• W2183455959 hasVolume "3" @default.
• W2183455959 isParatext "false" @default.
• W2183455959 isRetracted "false" @default.
• W2183455959 magId "2183455959" @default.
• W2183455959 workType "article" @default.